Nov 07, 2018
MiMedx Receives Nasdaq Delisting Notification
Nov 06, 2018
MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference
Oct 31, 2018
MiMedx to Present Clinical and Scientific Studies at SAWC Fall Meeting
Sep 25, 2018
MiMedx Publishes Positive Results From Clinical Study Of Human Umbilical Cord For Diabetic Foot Ulcers
Sep 20, 2018
MiMedx Announces Nasdaq Listing Extension
Aug 24, 2018
MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®
Aug 15, 2018
MiMedx Receives Additional Nasdaq Listing Notice Due to Late Form 10-Q
Aug 15, 2018
MiMedx Provides Additional Information and Context to Wall Street Journal Article
Aug 13, 2018
MiMedx announces Nasdaq listing extension and Hearing Date
Aug 09, 2018
MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia
Aug 02, 2018
MiMedx Announces Publication Of Phase 2B Clinical Trial Efficacy Data For Micronized dHACM In The Treatment Of Plantar Fasciitis In Foot & Ankle International
Aug 01, 2018
Schubert Jonckheer & Kolbe LLP Launches Investigation into Possible Breaches of Fiduciary Duty by MiMedx Group, Inc.'s Directors and Officers
Jul 26, 2018
MiMedx Announces Receipt of Nasdaq Letter
Jul 18, 2018
MiMedx Appoints Mark Graves Chief Compliance Officer To Strengthen Corporate Compliance Practices
Jul 10, 2018
Hynes Keller & Hernandez, LLC Announces Investigation of MiMedx Group, Inc. (MDXG)
Jul 02, 2018
MiMedx Announces Leadership Changes And Corporate Actions
Jun 07, 2018
MiMedx Announces Executive to Lead its International Operations and Provides Update on Company's International Progress
Jun 07, 2018
MiMedx to restate certain historical financial statements
May 18, 2018
MiMedx Receives NASDAQ Notice of Late Form 10-Q Filing
May 10, 2018
MiMedx Comments On Matters Related To Former VA Employees